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ABSTRACT
Prostate cancer tumor growth and neovascularization is
promoted by an interplay between migratory tumor stro-
mal cells such as specialized tumor-associated macro-
phages (TAMs) and circulating endothelial precursor cells
(CEPs). As vehicles for tumor therapy, human CEPs are
relatively easy to isolate from peripheral blood, are able to
proliferate long-term in vitro, are amenable to viral
manipulation, and preferentially home to regions of ische-
mia found in growing tumors. We show here that human
peripheral blood CEPs expanded ex vivo migrate to pros-
tate cancer cells in vitro and efﬁciently home to human
prostate tumor xenografts in vivo. Infection of precursors
ex vivo with an adenovirus constructed to secrete a soluble
form of the colony-stimulating factor-1 receptor CD115
that inhibits macrophage viability and migration in vitro
signiﬁcantly decreases the number of TAMs in xenografts
(p < .05), reduces proliferation (p < .01) and vascular
density (p < .03), and suppresses the growth of xenografts
(p < .03). These data show for the ﬁrst time that targeting
stromal cell processes with cellular therapy has the poten-
tial to retard prostate tumor growth. STEM CELLS
2009;27:2342–2352
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INTRODUCTION
Tumor development is characterized by complex interactions
between cancer cells, tumor stroma cells, and the extracellular
matrix (ECM). Neovascularization is essential for primary
solid tumors and secondary metastases to grow beyond 1-2
mm [1]. Microvessels may develop either from existing capil-
lary networks by neoangiogenesis and arteriogenesis, from
bone marrow (BM)-derived angioblasts, or circulating endo-
thelial progenitors (CEPs) in a process known as vasculogene-
sis [2].
Specialized stromal mononuclear phagocytes known as
tumor-associated macrophages (TAMs) also play a key role
in tumor neovascularization [3]. TAMs are derived from a
minor subpopulation of circulating monocytes [4] and are
proangiogenic in tumor regions of hypoxia [5], promoting
ECM remodeling by producing matrix metalloproteases,
secreting proangiogenic growth factors such as vascular
endothelial growth factor (VEGF), and stabilizing the tumor
vasculature [6]. TAM recruitment to solid tumors is strongly
mediated by colony-stimulating factor-1 (CSF-1) acting
through the receptor tyrosine kinase CD115 (also known as
the CSF-1R product of c-fms) expressed by TAMs [7]. In
breast [8] and prostate [9] cancer, TAM accumulation is
associated with poor prognosis and survival. Inhibition of
TAM recruitment and survival by targeting CSF-1 and
CD115 in breast cancer models has a signiﬁcant effect on
tumor development [10, 11].
The capability to transplant autologous, nontransformed
cell populations that migrate to sites of tumorigenic develop-
ment to deliver targeted, antitumor therapy has been a long-
term goal of cellular cancer therapy. By targeting biological
processes obligatory to tumorigenicity, cellular therapies have
the potential to circumvent the development of treatment
resistance associated with the instability of cancer cell
genomes. Endothelial precursors (EPs) have been isolated
from BM, ESCs, and cord blood [12] but circulate in the
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marker expression and expanded in an undifferentiated state
to therapeutical levels before undergoing senescence [13].
Although the precise role played by EPs to support the neo-
vasculature is controversial [14], EPs are effective at selec-
tively migrating to solid tumors [15, 16]. Almost one in six
men will be diagnosed with prostate cancer during their life-
time. Although the second leading cause of death from can-
cer, prostate cancer is a relatively slow-growing malignancy
that may be amenable to the applications of cellular therapy
[17]. CEPs are increased in the peripheral blood of prostate
cancer patients [18], and TAMs also play a crucial role in the
development and metastasis of prostate tumors [9]. The poten-
tial for viral transduced BM-derived cells to deliver soluble
antiangiogenic receptors to tumors has been shown [19]. We
therefore hypothesized that human ex vivo expanded CEPs
would migrate to human prostate tumors and may be used to
inhibit TAM-mediated tumor development by secretion of the
extracellular ligand binding domain of CD115.
MATERIALS AND METHODS
Generation of an Adenovirus-Expressing
Soluble CD115
A plasmid containing mouse CD115 was a kind gift of Professor
Richard Stanley (Albert Einstein College of Medicine, New
York). A soluble (s) mouse CD115 molecule was constructed
by amplifying the normal CD115 open reading frame start
consensus in a forward primer (50-GGAATTCCACCATG-
GAGTTGGGGCCTCCT-30) incorporating an EcoR1 linker and
truncating the molecule at nucleotide 1530 (GenBank accession
no. NM_007779.1) directly proximal to the membrane spanning
domain of the open reading frame with a reverse primer (50-
CGGGATCCCGTTACTCATCGGGGAGCTGCTT-30) incorporat-
ing a BamH1 linker. The 2,277-bp construct was gel puriﬁed
with Qiaex II (Qiagen, Hilden, Germany, http://www1.qiagen.
com) and ligated into the EcoR1 and BamH1 sites of the pDNR-
CMV donor vector, in which the MCS and distal chloramphenicol
resistance gene are enclosed by loxp sites (Adeno-X expression
systems 2; Clontech, Palo Alto, CA, http://www.clontech.com) as
p(s)CD115 and the reading frame of isolated plasmids was con-
ﬁrmed by sequencing on a PRISM 3,100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, http://www.appliedbiosys-
tems.com). The plasmids pDNR and p(s)CD115 (200 ng) were
incubated with cre recombinase (100 ng) and recombined into the
Adeno-X backbone according to the manufacturer’s protocol. The
reaction mix was transformed into Electromax DH10B cells (Invitro-
gen, Carlsbad, CA, http://www.invitrogen.com) in a Genpulser (Bio-
Rad, Hercules, CA, http://www.bio-rad.com), recombinants were
selected on LB plates containing 7% (wt/vol) sucrose and 30 lg/ml
chloramphenicol (Sigma, St. Louis, http://www.sigma.com), and
genomic integration was conﬁrmed by polymerase chain reaction.
Genomic clones were ampliﬁed, the viral inverted repeats were
exposed by PacI digestion, and after puriﬁcation, the adenoviral ge-
nome was serum-free transfected into adherent HEK 293 cells with
Lipofectamine (Invitrogen) in the presence of Plus reagent for 4
hours and cultivated further in culture medium. After 7-14 days, cy-
topathic HEK293 cells were centrifuged and resuspended in phos-
phate-buffered saline (PBS), and cells were lysed by freeze/thaw
cycles in an ethanol-dry ice bath/37 C, cleared by centrifugation,
a n ds t o r e da t 70 C or used to propagate HEK293 infection.
Adeno-X-DSRed2 adenovirus for expressing red ﬂuorescent protein
(AdRFP) was obtained from Clontech and propogated in HEK293
(CRL-1573) culture. Viruses were puriﬁed with Adeno-X-maxi kits
(Clontech), and the infectious units were determined by hexon anti-
body staining of HEK293 infections (Adeno-X-rapid titer; Clontech).
Cell Culture, Transfection, Infection, and
Conditioned Medium
HEK293, L-929, CRL-2505 prostate cancer, and SW620 colon
carcinoma cells (American Type Culture Collection, Manassas,
VA, http://www.atcc.org) were maintained in a tissue culture
medium (TCM) of Dulbecco’s modiﬁed eagle medium (DMEM;
PAA Laboratories, Linz, Austria, http://www.paa.at), 50 U/ml
penicillin, and 250 lg/ml streptomycin (Gibco; Invitrogen) sup-
plemented with 10% fetal calf serum (culture medium), in a fully
humidiﬁed air atmosphere containing 5% CO2 at 37 C. CSF-1-
dependent CRL-2470 mouse macrophages (American Type Cul-
ture Collection) were routinely cultured in TCM supplemented
with 10% L-929 ﬁbroblast conditioned medium as a source of
CSF-1 [20]. Human CEPs were isolated from peripheral blood
mononuclear cells from healthy donors on type I collagen
(Sigma) and expanded in EGM-2 medium (Lonza, Basel, Switzer-
land, http://www.lonza.com) as described previously [13] for at
least 10 population doublings before commencement of experi-
ments. Human CEPs proliferate in vitro for more than 30 popula-
tion doublings before entering senescence [13]. Subconﬂuent CEP
cultures were infected with AdCntl, AdRFP, or Ad(s)CD115 at a
multiplicity of infection of 100 for 24 hours and subsequently
labeled with DilC18 (Molecular Probes; Invitrogen). CEP condi-
tioned medium was prepared by replacing the culture medium
with serum- and growth factor-free basal medium and collecting
supernatants after 48 hours of culture. Plasmids were serum-free
transfected in HEK293 cells at semiconﬂuence with Lipofect-
amine in the presence of Plus reagent (Invitrogen) for 4 hours,
refed with culture medium, and cultured for 48 hours. Cells
layers were washed with PBS and incubated for 24 hours in se-
rum-free TCM before isolation of cellular supernatants. SW620
and CRL-2505 conditioned media were produced by cultivating
semiconﬂuent cell layers in 6-well plates for 24 hours in 2 ml of
nonsupplemented TCM. All supernatants were aliquoted, ﬂash
frozen, and stored at –80 C.
Migration and Proliferation Assays
CEPs were labeled with DilC18 and resuspended in serum-free
TCM, and 10
5 cells were applied to the top of a modiﬁed Boyden
chamber (8-lm pore size, Thincert 12-well format; Greiner Bio-
one, Frickenhausen, Germany, http://www.gbo.com/en). Migration
was assessed after 8 hours to nonsupplemented TCM, conditioned
medium, or conﬂuent CRL-2505 or SW620 tumor cell layers in
the bottom of the chamber. Cells surviving on tumor cell layers
were photographed up to 3 days later with an inverted ﬂuores-
cence microscope (Nikon Eclipse; Nikon, Du ¨sseldorf, Germany,
http://www.nikonUSA.com). CRL-2470 cells were starved of
growth factor for 48 hours in nonsupplemented TCM. Serum was
removed for 2 hours, and the medium was replaced with condi-
tioned medium from serum-starved HEK293 cells transfected
with pDNR or p(s)CD115 or endothelial progenitor cells (EPCs)
infected with AdCntl or Ad(s)CD115. Cells were restimulated
with the indicated concentrations of recombinant human (rh)CSF-
1 (Chiron, Emeryville, CA, http://www.), and proliferation was
assessed with the water soluble tetrazolium (WST) assay after 24
hours. CRL-2470 macrophages were starved of growth factor for
48 hours and labeled with DilC18, and 10
5 cells were applied to
the top of a modiﬁed Boyden chamber (Greiner Bio-one). Migra-
tion was assessed after 8 hours to a conﬂuent CRL-2505 stroma
layer in the bottom of the chamber in EPC conditioned medium
in the presence of rhCSF-1 as a chemoattractant.
Western Blotting
Transfected HEK293 cells were serum starved and supernatants
collected after 24 hours. Supernatants were Western blotted
(50 ll) onto nitrocellulose membranes (Bio-Rad) and incubated
with polyclonal rabbit antibody directed against the extracellular
domain of mouse CD115 (US Biological, Swampscott, MA,
http://www.usbio.com) and horseradish peroxidase-conjugated
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http://www.gehealthcare.com). Proteins were detected by chemi-
luminescence (Supersignal-West- Femto; Pierce, Rockford, IL,
http://www. piercenet.com) and quantiﬁed by Easy Win 32 soft-
ware (Herolab, Wiesloch, Germany, http://www.herolab.com).
Tumor CEP Homing In Vivo
All experiments were approved by the Institutional Animal Care
and Use Committee at the Vienna Medical University. Male,
pathogen-free 5-week-old nu/nu (nude) mice (Harlan-Winkelmann,
Borchen, Germany, http://www.harlan.com) were weighed and
anesthetized (ketamine hydrochloride/xylazine at 55/7.5 mg/kg,
i.p.), and 15   10
6 CRL-2505 cells in 150 ll PBS were injected
subcutaneously into the left ﬂank. Tumor growth was monitored
daily with calipers, and animals with comparable tumors were
coded and divided into experimental groups after 10 days. Tumor
volumes were calculated as length   width
2   0.5. Mice were
anesthetized, and 10
7 CEP-DilC18 cells were systemically intro-
duced by injection into the left ventricle. Animals were sacriﬁced
36 hours or 3 or 13 days later, and the tumors were isolated and
weighed. Because of tumor homing failure as a consequence of the
injection procedure in 13% of cases, tumors were included into
groups where tumor CEP-DilC18 levels exceeded 1.5%.
Fluorescent Activated Cell Sorter Analysis
Tumors sections were rinsed in PBS, minced, mechanically disso-
ciated after collagenase digestion at 37 C for 30 minutes, and
passed through a 100-lm cell strainer. Mouse peripheral blood
was collected by tail vein puncture into heparin-coated tubes
(Greiner Bio One). Erythrocytes were lysed in 155 mM NH4Cl,
10 mM KHCO3, and 0.1 mM EDTA, pH 8, for 10 minutes at
4 C. Isolated cells and AdRFP-infected CEPs in vitro were
washed in PBS, and 10
4 viable events were analyzed on a FACs-
can ﬂow cytometer (BD Biosciences, San Diego, http://
www.bdbiosciences.com) with an argon laser tuned to 488 nm.
Membrane-compromised cells were excluded with 7AAD (BD
Biosciences). CEPs were stained with phycoerythrin- and ﬂuores-
cein isothiocyanate-conjugated monoclonal antibodies against
CD14 (Immunotools, Friesoythe, Germany, http://www.immuno-
tools.com), CD31 (BD Biosciences), CD34 (BD Biosciences),
CD45 (BD Biosciences), CD133 (Miltenyi Biotech, Bergisch
Gladbach, Germany, http://www.miltenyibiotec.com), CD141 (BD
Biosciences), CD146 (Chemicon, Temecula, CA, http://www.
chemicon.com), and VEGFR2 (R&D Systems, Minneapolis,
http://www.rndsystems.com as described previously [13].
Histology
Tissue samples were ﬁxed in formalin and parafﬁn embedded.
Sections were rehydrated in graded alcohols, and antigen retrieval
was performed in a microwave in 0.1 M sodium citrate (pH 6.5).
Sections were blocked in PBS supplemented with 5% horse se-
rum and stained with monoclonal rat anti-mouse F4/80 (Abd
Serotec, Kidlington, U.K., http://www.abdserotec.com), rabbit
anti-human Ki-67 (Thermo Scientiﬁc, Fermont, CA, http://
www.thermo), rabbit anti-human and mouse von Willebrand fac-
tor (vWF; Abcam, Cambridge, U.K., http://www.abcam.com), or
irrelevant isotype matched control antibodies (BD Biosciences).
Primary antibodies were detected by sequential incubation with
appropriate biotinylated secondary antibodies (Vector Laborato-
ries, Burlingame, CA, http://www.vectorlabs.com) and Alexa
Fluor 488-conjugated streptavidin (Molecular Probes; Invitrogen)
or horseradish peroxidase-conjugated streptavidin (DAKO,
Glostrup, Denmark, http://www.dako.com). Slides were rinsed
with PBS and stained with 0.1 lg/ml 40-6-diamidino-2-phenylin-
dole, mounted in Cityﬂuor, and analyzed on a ﬂuorescent micro-
scope (Zeiss, Thornwood, NY, http://www.zeiss.com). Ki-67
þ
proliferating cells, rabbit anti-human, and mouse vWF (Abcam)-
positive capillaries and F4/80
þ TAMs were counted in 10 consec-
utive (magniﬁcation,  20) ﬁelds per slide, and results are
expressed as cells per section.
Kupffer Cell Isolation and Phagocytosis Assays
Kupffer cell populations were isolated 3 days after CEP injection
essentially as described previously [21]. Brieﬂy, mice were anes-
thetized, the peritoneal cavity was exposed, a 24-gauge cannula
was inserted into the vena porta, and the liver was perfused for
2 minutes with Ca
2þ-free Hank’s buffered salt solution (PAA),
allowing the blood to drain from an incision in the inferior vena
cava. After a further perfusion for 30 seconds with DMEM sup-
plemented with 0.163 U/ml collagenase A (Sigma), the liver was
removed, minced, and incubated with agitation at 35 C for
10 minutes in DMEM/collagenase, passed through a 100-lm ﬁlter
(BD Biosciences), and resuspended in DMEM supplemented with
2 lg/ml DNase. Cells (10
6/well) were seeded in 6-well plates and
cultured for 2 hours at 37 C in culture medium, nonadherent cells
were removed, and cultures were refed with 3 ml of culture
medium supplemented with 1 ll/ml ﬂuorescent latex beads
(Sigma) with an average size of 1 lm. Cells phagocytosing more
than 10 beads were scored by ﬂuorescent microscopy after
24 hours. Results are expressed as numbers of phagocytes per
well in triplicate.
Statistical Analysis
The Mann-Whitney U-test for unpaired groups was used to com-
pare data between the groups. All statistical tests were two sided.
Statistical tests were performed with the use of SPSS software
(version 10.0.7; SPSS, Chicago, IL, http://www.spss.com). P <
0.05 indicated statistical signiﬁcance.
RESULTS
Isolation, Expansion, and Characterization of
Human CEPs
The human CEPs described here are routinely cultured from
peripheral blood mononuclear cells by adherence to type 1
collagen-coated ﬂasks and are characterized by a high prolif-
erative potential and lack of spontaneous differentiation in
response to angiogenic growth factors [13]. Distinct from de-
velopment of circulating endothelial cells (CECs) and the col-
ony-forming unit endothelial cells (CFU-ECs) that also have
the potential to adhere in vitro but show limited proliferative
capacity, CEPs more closely resemble circulating endothelial
progenitors (EPC/CEP), endothelial colony-forming cells
(ECFCs), or blood outgrowth endothelial cells (BOECs),
shown diagrammatically in Figure 1A; these have been previ-
ously described [22, 23]. Low- and high-passage CEPs show
a stable surface antigenic proﬁle expressing endothelial cell
antigens (CD146, CD141, CD31, and VEGFR2) but lacking
blood (CD45) or myeloid (CD14) cell markers (Fig. 1B). Cul-
tured CEPs express low levels of CD34 but, in contrast to
EPC/CEPs, lack expression of CD133 (Fig. 1B), which is
most likely lost during adhesion and propagation.
Human Ex Vivo Expanded CEPs Migrate to
Prostate Cancer Cells In vitro
We initially screened a panel of tumor cell lines and condi-
tioned medium for activities to promote the migration and
survival of CEPs in vitro. Summarized in Figure 2A, both
CRL-2505 prostate cancer conditioned medium and conﬂuent
CRL-2505 cell layers signiﬁcantly promoted the serum-free
migration of DilC18 ﬂuorescently labeled CEPs (CEP-
DilC18) in vitro compared with tissue culture medium or a
cell line lacking this activity such as SW620 colon cancer
cells (p < .001). In the serum-free cell layer cultures, 1.14  
0.33% (mean of three experiments) of migrating CEPs also
extended cytoplasmic processes on the CRL-2505 cell layer
2344 Cellular Tumor Therapy Targeting TAMs(Fig. 2B) not seen in SW620 cells (Fig. 2C). These data show
that CRL-2505 prostate cancer cells can promote the migra-
tion and serum-free survival of human CEPs in vitro.
Human Ex Vivo Expanded CEPs Home to Human
Xenotransplanted Prostate Tumors In Vivo
To determine whether human ex vivo expanded CEPs migrate
to CRL-2505 in vivo, subcutaneous tumors were implanted in
immune compromised athymic nu/nu mice for 10 days, and
10
7 CEP-DilC18 were systemically introduced by intraventric-
ular injection. Shown representatively in Figure 3A, ﬂuores-
cent activated cell sorter (FACS) analysis of isolated tumor
lysates demonstrated that 2.4   1.3% of the tumor was made
up of CEP-DilC18s 3 days after injection. The rather large
variation in CEP-DilC18 scatter characteristics observed is
consistent with the variable morphologies adopted by EPs in
the tumor microenvironment [24]. In tissue sections, nucleated
CEP-DilC18s were located throughout the growing CRL-2505
tumor at densities corresponding to the FACS analysis data,
indicating stability of the DilC18 dye during tissue embedding
and ﬁxation (Fig. 3B). Deﬁning the peritumoral space as the
Figure 1. Immunophenotype of human CEPs expanded in vitro. (A): Schematic representation of surface antigenic changes in different charac-
terized endothelial cell progenitor populations. Highly proliferative cell lineages are colored red. (B): Representative ﬂow cytometric staining of
highly proliferative, low and high passage CEPs show stable expression of CD146, CD141, CD31, and VEGFR2, low levels of CD34, and a lack
of CD14, CD45, and CD133 antigen expression. Abbreviations: BOEC, blood outgrowth endothelial cell; CEC, circulating endothelial cell; CEP,
circulating endothelial precursor cell; CFU-EC, colony forming unit-endothelial cell; ECFC, endothelial colony-forming cell; EPC, endothelial
progenitor cell; HPC, hematopoietic progenitor cell.
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uted within the tumor. Analysis of serial sections showed that
77.3   7.9% and 74.64   12.3% of tumoral CEP-DilC18s
were localized to the actively growing peritumoral region 3
and 13 days after administration, respectively, shown repre-
sentatively in Figure 3B, in the vicinity of peritumoral Ki-67
þ
proliferating tumor cells (Fig. 3C). We next assessed the tis-
sue distribution of CEP-DilC18s in different organs. Similar
to tail vein injection of human EPCs [16], the highest density
of introduced CEPs accumulated in tumor tissue (1,991  
370 cells/section), signiﬁcant numbers were found in the
spleen (237   44), and only low levels (<37 cells/section)
were found in other major organs (liver, kidney, lung, and
brain) examined 13 days after injection (Fig. 3D). To study
the kinetics of circulation and homing of CEP-DilC18s in the
initial stages after injection, we assessed levels in the periph-
eral blood and tumors 36 and 72 hours after injection by ﬂow
cytometry (Fig. 3E, 3F). Data indicate that levels of tumor-
associated CEP-DilC18s increase between 36 and 72 hours
after injection (p ¼ .03). Although differences in CEP levels
between time points in peripheral blood did not reach statisti-
cal signiﬁcance, a clear trend toward increased circulating
levels could indicate the presence of extravasation processes
of the administered CEP-DilC18s.
Together these data show that expanded CEPs preferen-
tially migrate to the actively growing peritumoral region of
prostate cancer tumors in vivo and are cleared from the circu-
lation primarily in the spleen.
Construction and Infection of CEPs with
Adenoviruses
To evaluate the potential of CEP as transient carriers of a poten-
tial therapeutic protein in a nonintegrative virus, we assessed
the transfection efﬁciency of CEP with a nonintegrative DE1/
DE3 red ﬂuorescent protein expressing adenovirus (AdRFP)
in vitro. As shown in Figure 4A, 74   13% of CEPs are
infected by adenoviruses in vitro as assessed by ﬂow cytometric
analysis and ﬂuorescence microscopy. Expression of RFP was
maintained for up to 13 days in vitro (data not shown). As
shown in Figure 4B, CD115 is an integral transmembrane
receptor with ﬁve immunoglobulin-like extracellular domains
dependent for binding of CSF-1 and receptor dimerization and
a juxtamembrane domain proximal to transmembrane insertion
[25]. A construct containing the leader peptide and extracellular
domains of mouse CD115 deleting the transmembrane compo-
nent and intracellular signaling domains is efﬁciently secreted
by insect cells and effectively binds CSF-1 [26].
To produce a cell therapy CEP-based inhibitor of CSF-1
signaling to speciﬁcally target the host stromal compartment,
the leader peptide and extracellular domains of mouse CD115
were inserted into the pDNR-CMV donor expression plasmid
as p(s)CD115. Transient transfection of HEK293 cells with
p(s)CD115 resulted in secretion of the 72-kDa soluble recep-
tor as shown by Western blotting of serum-free culture super-
natants (Fig. 4B). After recombination into the adenoviral
backbone and viral production in trans-complementing
HEK293 cells, puriﬁed Ad(s)CD115 was used to infect CEPs
in vitro. As shown in Figure 4B, CEPs secrete the 72-kDa
(s)CD115 receptor after infection with the soluble receptor
virus. Secreted protein concentrations were 1.7-fold higher in
Ad(s)CD115-infected CEPs than p(s)CD115-transfected
HEK293 cells, reﬂecting increased expression from the
adenovirus. Serum-free supernatants from HEK293 cells tran-
siently transfected with p(s)CD115 and CEP infected with
Ad(s)CD115 (Fig. 4C) inhibited CSF-1-driven proliferation of
mouse CRL-2470 macrophages in vitro at pretitrated, saturat-
ing (1,000 IU/ml), and supersaturating (5,000 IU/ml) concen-
trations of rhCSF-1 (p < .001). Representative images of the
effect of p(s)CD115 supernatants on CRL-2470 are shown in
Figure 4D. Serum-free supernatants from Ad(s)CD115-infec-
teds CEP also signiﬁcantly inhibit the CSF-1-dependent
migration of CRL-2470 macrophages in vitro (Fig. 4D). These
Figure 2. CRL-2505 prostate cancer cells promote CEP migration
in vitro. (A): CRL-2505 CM and conﬂuent CLs signiﬁcantly promote
the migration of DilC18-labeled CEPs (CEP-DilC18) in vitro compared
with SW620 colon cancer cells and serum-free TCM controls (*, p <
.001). (B): In CL cultures, in addition to CEPs scored in suspension
(arrow), a signiﬁcant number of migrated CEP-DilC18s also extend
cytoplasmic processes on the underlying tumor cell layer after 48 hours
(magniﬁcation,  20). (C): In SW620 CL cultures, only CEP-DilC18s
in suspension are observed (magniﬁcation,  20). Abbreviations: CEP,
circulating endothelial precursor cell; CL, cell layer; CM, conditioned
medium; CL, cell layer; TCM, tissue culture medium.
2346 Cellular Tumor Therapy Targeting TAMsdata show that CEPs can be infected to express a soluble
CD115 receptor construct from an adenovirus that can sup-
press the proliferation and migration of macrophages in vitro.
Cellular Tumor Targeting of TAMs
We next studied whether exogenous CEPs could potentially
inhibit TAM recruitment to tumors by infection with
Ad(s)CD115. All experiments in vivo were limited to the
time span of protein expression from the episomal adenovirus
determined in vitro. In preliminary experiments, we showed
that native CEPs do not express CD115 in FACS analysis and
that infection with Ad(s)CD115 did not inﬂuence EPC migra-
tion to CRL-2505 cell layers in vitro (data not shown).
When CEPs were infected with AdCntl or Ad(s)CD115
virus, subsequently labeled with DilC18 and injected into
CRL-2505 bearing nu/nu mice, CEP migrated to the tumor
Figure 3. CEPs preferentially
home to CRL-2505 prostate can-
cer xenografts in vivo. CEP-
DilC18s were introduced into
mice bearing established CRL-
2505 xenografts. (A): Represen-
tative ﬂow cytometric side scat-
ter plot analysis showing that
2.4   1.3% of tumor material is
comprised of CEP-DilC18s 3
days after administration com-
pared with control xenografts.
(B): Representative ﬂuorescence
microscopy images of exoge-
nous CEP-DilC18s migrated to
xenotransplanted CRL-2505
tumors shows CEP-DilC18s are
found throughout the tumor (left
panel; magniﬁcation,  40; bar,
20 lm). (C): Representative
images show that CEP-DilC18s
colocalize with tumor cells
staining for Ki-67
þ (Alexa-ﬂuor
488, green; nuclear counterstain,
diamidino-2-phenylindole, blue)
in the peritumoral space within
20 cell layers of the TB 13 days
after injection. (D): In major
organs, exogenous CEP-DilC18s
are primarily found in the tumor
(*, p < .001) compared with all
other organs after 13 days. (E):
Detection of CEP-DilC18s in
peripheral blood and tumors 36
and 72 hours after injection (*,
p ¼ .03). (F): A representative
ﬂuorescent activated cell sorter
histogram showing levels of
CEP-DilC18s in peripheral
blood after 72 hours compared
with control mice. Abbrevia-
tions: CEP, circulating endothe-
lial precursor cell; Cntl, control;
TB, tumor boundary.
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www.StemCells.comFigure 4. Adenovirus construction and circulating endothelial precursor cell (CEP) infection. (A): Marker adenovirus infection of endothelial
progenitor cells at a multiplicity of infection of 100 results in expression of red ﬂuorescent protein in more than 74   13% of cells assessed by
ﬂow cytometry and ﬂuorescence microscopy. (B): An (s)CD115 receptor was constructed by cloning the ligand binding extracellular domains of
CD115 proximal to the transmembrane domain (dotted line) into the pDNR donor vector as p(s)CD115 and inserted into an adeno-X adenoviral
backbone as Ad(s)CD115. Both p(s)CD115 transiently transfected HEK 293 cells and Ad(s)CD115-infected CEPs secrete the 72-kDa (s)CD115
protein in vitro shown in representative Western blots. (C): Serum-free supernatants from p(s)CD115-transfected and Ad(s)CD115-infected
cultures signiﬁcantly inhibit CSF-1-driven proliferation of CRL-2470 mouse macrophages in vitro (*, p < .001). (D): Representative images of
the effect of p(s)CD115 supernatants on CRL-2470 are shown (magniﬁcation,  20). Serum-free supernatants from Ad(s)CD115-infected CEPs
signiﬁcantly inhibit the migration of CRL-2470 in vitro (*, p < .001). Abbreviations: CSF-1, colony-stimulating factor-1; (s), soluble.
2348 Cellular Tumor Therapy Targeting TAMsand organs with similar kinetics to noninfected CEP-DilC18
(data not shown). In the Ad(s)CD115 group, signiﬁcant reduc-
tions in the growth of xenografts were seen from 11 days
after CEP injection (p < .05 and p < .02 between
Ad(s)CD115 and both Cntl and AdCntl groups on days
11 and 13, respectively; Fig. 5A, left panel). At termination
13 days after CEP injection, tumor masses (311   97 mg)
were signiﬁcantly (p < .03) reduced in the Ad(s)CD115 group
compared with the AdCntl (428   85 mg) and Cntl (416  
33 mg) groups (Fig. 5A, right panel). No signiﬁcant differen-
ces in the weight of mice between the groups were observed
(data not shown).
In CRL-2505 xenotransplants, F4/80
þ TAMs are detected
frequently in perivascular regions neighboring acellular areas
of extracellular matrix remodeling (Fig. 5B, left panel) and in
the peritumoral region colocalizing with exogenous CEP-
DilC18s (Fig. 5B, center panel) of the growing tumor. Assess-
ment of the total number of F4/80
þ cells (Fig. 5B, right
panel) in tumor sections showed a signiﬁcant reduction (p <
.05) in TAM densities from 58.6   16.9 to 33.8   9.7 cells/
section in the Ad(s)CD115 group compared with the AdCntl
group. F4/80
þ TAM densities were decreased 2.62- and 1.42-
fold in the peritumoral and central regions of the tumor,
respectively. Accompanying the reduction in tumor growth,
Ki-67
þ proliferating cells were signiﬁcantly (p < .01) reduced
in the Ad(s)CD115 group (14.8   5.3 cells/section) compared
with the AdCntl group (46   13.8; Fig. 5C). Reductions in
Ki-67
þ cells were observed homogenously throughout the
tumor. Assessment of tumor vascularity by counting vWF-
positive tumoral vessels (Fig. 5E) distinct from tumoral vWF-
expressing CEPs, also detected by the antibody used,
additionally showed that TAM reduction was associated with
signiﬁcantly reduced numbers of capillaries throughout the
tumor (p < .03). These data suggest that, although reduced
throughout the tumor, localized effects on TAM densities
are increased in the peritumoral compartment where
Ad(s)CD115-infected CEP-DilC18s and TAM colocalize,
leading to reductions in cancer cell proliferation and vascular
density throughout the tumor.
To assess whether Ad(s)CD115-infected CEPs may inﬂu-
ence the function of other phagocytes, we isolated Kupffer
cells from liver homogenates 3 days after CEP administration.
No statistical differences were observed in the ability to phag-
ocytose ﬂuorescent latex beads between the AdCntl- and
Ad(s)CD115-infected CEP groups (Fig. 5E). Taken together,
these data suggest that (s)CD115-expressing CEPs migrate to
prostate cancer tumors in vivo to inhibit TAM levels, reduce
tumor cell proliferation, and suppress tumor growth.
DISCUSSION
In this study, we showed that exogenous ex vivo expanded
human CEPs infected with a therapeutic adenovirus speciﬁ-
cally migrate to human prostate xenografts in nude mice to
suppress tumor growth. The capacity for different EP popula-
tions to integrate into the neovasculature in regions of ische-
mia of solid tumors has varied between different studies [27].
Syngenic BM-derived EPs incorporate into the vasculature of
Lewis lung carcinoma [28] and are responsible for the angio-
genic switch in lung metastasis [29]. In a variety of human
cancers, BM-derived ECs have been found to contribute up to
5% of the tumor endothelium [30]. More recently, a more
perivascular role for CEPs has been shown in a variety of
mouse models [14]. Differences in results between studies
may in part be attributed to the degree of fractionation and
culture of studied EP populations from embryonic, BM, cord,
and peripheral blood origins, combined with myeloablation
protocols to suppress endogenous BM-derived EP homing.
However, in almost all models, EPs have been shown to
selectively migrate to tumors.
In studies using exogenous in vitro expanded human
EPCs in mouse models, tail vein-injected EPCs form vascular
structures in autologous tumors [15] and orthotopic human
glioblastoma in SCID mice [16]. Endothelial colony-forming
cells isolated by adherence to type I collagen also form func-
tional, chimeric microvessels in ﬁbronectin/collagen implants
in NOD/SCID mice [22]. In this study, no evidence was
found of exogenous human EPC incorporation into the host
nu/nu mouse vWF
þ tumor neovasculature (data not shown),
but, similar to human glioblastoma [16], CEPs homed primar-
ily to the spleen and the growing tumor, preferentially localiz-
ing to the peritumoral region. Although discrepancies between
studies may be caused by different mouse models or of i.v.
application routes, these results have relevance for any poten-
tial therapeutical utilization of CEP homing to tumors because
administered CEPs could potentially contribute to the neovas-
culature and promote tumor growth.
CEP transplantation can support therapeutical postisch-
emic neovascularization in a variety of tissues [31]. Coinjec-
tion of EPC with cancer cells also increases tumor growth in
mice [32] and is associated with stabilization of the neovascu-
lature that can be reversed by prior EPC irradiation [33]. No
reports have shown to date that systemically administered
EPCs inﬂuence tumor development, and migrated CEPs in
this study did not promote the growth of the established pros-
tate tumors compared with untreated controls. Homing of
administered CEPs would be expected to compete with
endogenous BM-derived CEPs in the later stages of tumor
development [28], which may not be the case in coinjection
experiments.
The ease of isolation, self-renewal in vitro, amenability to
infection with viruses, and tumor homing capacity of EPCs
have been proposed as vehicles for targeted tumor therapy
[34]. Embryonic EPs have been used as cellular therapy car-
riers to locally deliver a 5-ﬂuorouracil prodrug to lung metas-
tasis [35]. Homing of unfractionated BM-expressing soluble
VEGFR2 as an angiogenesis inhibitor suppresses tumor
growth [19], although expression of such a soluble receptor
could theoretically affect the VEGF-dependent tumoral migra-
tion of EPCs [15].
An additional process pivotal to the growth of tumors
such as prostate cancer is the migration and inﬁltration of
proangiogenic TAMs [9]. TAMs are a distinct subpopulation
of mononuclear phagocytes derived from circulating Tie-2-
expressing monocytes that express CD115 [4]. Strategies to
target TAMs in prospective cancer therapy [36] have included
directly targeting TAM legumain expression with a DNA vac-
cine [37], the use of chemokine receptor antagonists [38], and
TAM re-education from M2 type macrophages to a more
proinﬂammatory, tumoricidal phenotype [39]. Monocyte and
macrophage chemotaxis and survival is strongly regulated by
the growth factor CSF-1 produced by a variety of cells
including ﬁbroblasts, mononuclear phagocytes, and prostate
cancer cells [40, 41], and reducing intratumoral and systemic
CSF-1/CD115 has been shown to suppress breast cancer
growth [10, 11]. In this study, we showed the efﬁcacy of
adapting this strategy for the potential treatment of prostate
tumors with cellular therapy delivering a soluble CSF-1 recep-
tor antagonist with a nonintegrative viral strategy to locally
reduce TAM levels.
A number of clinical trials have been conducted with ther-
apeutical EPs and different fractions of mononuclear cells. To
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www.StemCells.comFigure 5. Cellular therapy targeting tumor-associated macrophages. (A): Intracardial injection of ringer solution (Cntl) and exogenous CEP-
DilC18s infected with AdCntl or Ad(s)CD115 virus signiﬁcantly inﬂuenced the growth of established CRL-2505 xenografts at the indicated time
points (
‡, p < .05,
†, p < .02; data   SEM) after CEP-DilC18 injection. At termination on day 13 after adenovirus-infected CEP-DilC18 injec-
tion, a signiﬁcant reduction in the tumor masses of CRL-2505 was observed in the Ad(s)CD115 group (*, p < .03 compared with Cntl and
AdCntl groups, data   SEM; bar, 10 mm). (B): In CRL-2505 prostate tumors, representative images show TAMs staining positive for F4/80 anti-
gen (Alexa-488, arrowheads) primarily localized in perivascular regions within the tumor in the vicinity of AC areas of extracellular matrix
remodeling (left panel; magniﬁcation,  100; bar, 20 lm) or in the peritumoral compartment (right panel; magniﬁcation,  100; bar, 20 lm) in
the vicinity of the TB colocalizing with CEP-DilC18. The autoﬂuorescence of erythrocytes denotes the location of a tumoral capillary (nuclear
counterstain diamidino-2-phenylindole). Quantiﬁcation of F4/80
þ TAM levels shows signiﬁcant (p < .05) decreases in the Ad(s)CD115 group
compared with the AdCntl group. (C): Representative images (magniﬁcation,  40; bar, 20 lm) and quantiﬁcation show an associated signiﬁcant
decrease (p < .01) in the numbers of proliferating Ki-67-positive cells (arrowheads) in the Ad(s)CD115 group compared with the AdCntl group.
(D): Representative images (magniﬁcation,  60; bar, 20 lm) of von Willebrand factor staining and quantiﬁcation show a signiﬁcant (p < .03)
reduction in capillary densities in the Ad(s)CD115 group compared with the AdCntl group. (E): Kupffer cells isolated from AdCntl and
Ad(s)CD115 groups show a similar degree of ﬂuorescent latex bead phagocytosis (magniﬁcation,  4; bar, 10 lm; in vitro) 3 days after CEP
administration. Abbreviations: AC, acellular; CEP, endothelial precursor cell; Cntl, control; TB, tumor boundary.date, trials have primarily focused on the direct administration
of EPs to myocardial infarcts by intracoronary injection or
i.m. application for the treatment of critical limb ischemia
[42]. More recently, i.v. infusion of autologous EPs has also
been shown to be a feasible and safe methodology in the
treatment of patients with idiopathic pulmonary arterial hyper-
tension [43].
CONCLUSION
In this study, we showed that, by directly inﬂuencing the
localized accumulation of TAM with a soluble CSF-1 decoy
receptor expressed by transfusion of exogenous CEPs, a
reduction in the proliferative index and vascularity of tumors
is accompanied by direct suppression of prostate cancer
growth. These data may therefore lead to the use of CEPs in
the development of tailored, nontoxic, cellular therapy strat-
egies to combat the growth and development of prostate can-
cer by inhibiting the localized accumulation of TAM.
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